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Abstract
Large rare copy number variants (CNVs) have been recognized as significant genetic risk factors for the development of
schizophrenia (SCZ). However, due to their low frequency (1:150 to 1:1000) among patients, large sample sizes are needed
to detect an association between specific CNVs and SCZ. So far, the majority of genome-wide CNV analyses have focused on
reporting only CNVs that reached a significant P-value within the study cohort and merely confirmed the frequency of
already-established risk-carrying CNVs. As a result, CNVs with a very low frequency that might be relevant for SCZ
susceptibility are lost for secondary analyses. In this study, we provide a concise collection of high-quality CNVs in a large
German sample consisting of 1,637 patients with SCZ or schizoaffective disorder and 1,627 controls. All individuals were
genotyped on Illumina’s BeadChips and putative CNVs were identified using QuantiSNP and PennCNV. Only those CNVs
that were detected by both programs and spanned $30 consecutive SNPs were included in the data collection and
downstream analyses (2,366 CNVs, 0.73 CNVs per individual). The genome-wide analysis did not reveal a specific association
between a previously unknown CNV and SCZ. However, the group of CNVs previously reported to be associated with SCZ
was more frequent in our patients than in the controls. The publication of our dataset will serve as a unique, easily
accessible, high-quality CNV data collection for other research groups. The dataset could be useful for the identification of
new disease-relevant CNVs that are currently overlooked due to their very low frequency and lack of power for their
detection in individual studies.
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Introduction
Schizophrenia (SCZ) is a severe and debilitating neuropsychi-
atric disorder with a lifetime prevalence of 0.5–1%. Based on twin
studies, it was estimated that SCZ has a heritability of ,80% [1].
Several large copy number variants (CNVs) have been identified
as risk factors for SCZ susceptibility [2–14]. Among patients with
SCZ, the frequency of such CNVs is low and ranges between
1:150 and 1:1,000 [15]. The majority of published CNV studies
have focused on microduplications and microdeletions that reach
a nominally significant P-value, and thus these studies only report
the frequency of already-established risk-bearing CNVs. There-
fore, very rare CNVs that might be disease-relevant go undetected
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and unreported due to the limited sample sizes of current studies
and are consequently lost for follow-up studies. To help change
this, we set out to compile a concise collection of high-quality
CNV calls in a clinically well-characterized sample of 1,637
patients with SCZ or schizoaffective disorder (SCZA). Addition-
ally, using data from 1,627 controls we (i) performed a genome-
wide CNV analysis, and (ii) checked the frequency of CNVs
previously reported to be associated with schizophrenia.
Materials and Methods
Ethics statement
Each participant provided written informed consent prior to
inclusion and all aspects of the study complied with the
Declaration of Helsinki. The study was approved by the ethics
committees of all study centers: Ethics Committee of the
Rheinische Friedrich-Wilhelms-University Medical School in
Bonn, Ethics Committee ‘‘Medizinische Ethik-Kommission II’’
University of Heidelberg, Ethics Committee of the Friedrich-
Schiller-University Medical School in Jena, and Ethics Committee
of the Ludwig-Maximilians-University Munich.
In our study, we only included patients who had full capacity to
consent. The ability to consent was determined by the referring
psychiatrist. We did not enclose patients who were under care or
had a legal guardian. In exceptional cases, a patient with a legal
guardian wished to participate and we did not want to
discriminate against him/her by denying participation to the
study. In these rare cases, written informed consent was obtained
by both the patient and the legal guardian. At the recruiting site in
Jena, patients with a legal guardian, who wanted to be included in
the study, had to have full capacity to consent and no legal
obligation to obtain additional permission by their legal guardian.
All potential participants who declined to participate (for any
reason) were eligible for treatment and were not disadvantaged in
any other way by not participating in the study.
Sample description
All individuals were of German descent according to self-
reported ancestry. A total of 1,831 patients were recruited from
consecutive admissions to psychiatric inpatient units. A lifetime
‘‘best estimate’’ diagnosis [16] of SCZ or SCZA according to
DSM-IV criteria [17] was assigned on the basis of the Structured
Clinical Interview [18] or the OPCRIT [19], medical records, and
family history. A total of 1,643 controls were included. These are
described in detail elsewhere [20].
Genotyping and quality control
Venous blood samples were obtained from all participants.
These were genotyped separately using the following Illumina
BeadChips: HumanHap550v3, Human610-Quadv1, and Hu-
man660W-Quad. Only those markers common to all three chips
were analyzed. In total we analyzed 546,137 markers. To avoid
technical artifacts in CNV calling, stringent quality control criteria
were applied prior to computational CNV prediction, as described
in Degenhardt et al. [20].
CNV detection and CNV quality control criteria
Detailed information on CNV detection and CNV quality
control is provided elsewhere [20]. In brief, to identify potential
CNVs, the BeadChip data of each participant was analyzed with
QuantiSNP (version 2.1, http://www.well.ox.ac.uk/QuantiSNP;
[21]) and PennCNV (version 2010May01, http://www.
openbioinformatics.org/penncnv/; [22]). Individuals were exclud-
ed if their standard deviation from the log R ratio calculated over
all SNPs exceeded 0.30. CNVs were required to have a minimum
of 30 consecutive SNPs and a log Bayes Factor (lBF; QuantiSNP)
or confidence value (PennCNV) of at least 30.
Merging PennCNV and QuantiSNP CNV data
Only those CNVs that passed our filter criteria and that were
called by both QuantiSNP and PennCNV were included in our
analysis. All CNVs that are listed in the supplement were visually
inspected and confirmed using Illumina’s GenomeStudio Geno-





(n =1,627) P OR P-del OR-del P-dup OR-dup
1q21.1 144.94–146.29 [2,3,7] 3 del 1 del 0.62 2.98 0.62 2.98 – –
2p16.3 (NRXN1, gene affecting) 49.90–51.50 [4,5,7] 10 del, 1 dup 5 del, 0 dup 0.21 2.19 0.30 1.99 1 .1
3q29 197.2–198.83 [6,7,9] – – – – – – – –
7q36.3 158.51–158.63 [7,9] 1 dup – 1 .1 – – 1 .1
15q11.2 20.31–20.78 [3,11,12] 2 del 3 del 0.69 0.66 0.69 0.66 – –
15q13.3 28.72–30.30 [2,3,7,9,12] – – – – – – – –
16p13.11 (affecting interval II) 15.38–16.19 [10,11,12] 3 del, 2 dup 3 del, 0 dup 0.73 1.66 1 0.99 0.5 .1.99
16p11.2 29.57–30.21 [7,8,9] 1 dup – 1 .1 – – 1 .1
17p12 14.00–15.40 [11,12] – – – – – – – –
17q12 31.89–33.28 [12,13] – – – – – – – –
22q11.21 17.00–19.80 [3,7,9,14] 2 del – 0.50 .1.99 0.50 .1.99 – –
sum – – 20 del, 5 dup 12 del, 0 dup 0.05 2.09 0.21 1.66 0.06 .4.98
SCZ, schizophrenia; del, microdeletion; dup, microduplication; P, P-value; OR, odds ratio. Position according to NCBI built 36; all P-values and ORs were calculated using
Fisher’s exact test.
Two of the patients with a deletion in 1q21.1 and one patient with a deletion in 15q11.2 were already reported by Stefansson et al. [3], three patients with a deletion in
Neurexin were included in Rujescu et al. [5] and two patients with a deletion and one patient with a duplication in 16p13.11 were part of the study performed by
Ingason et al. [10].
doi:10.1371/journal.pone.0064035.t001
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typing Module (version 1.6.3, http://www.illumina.com/pages.
ilmn?ID=169; table S1). In cases where the two programs
identified differing CNV breakpoints, only the overlapping CNV
was reported. Rarely, one program detected one large CNV
whereas the other program identified two smaller CNVs. Based on
the visual inspection of the CNV and the SNP coverage in the
affected CNV region, the predicted CNV that was more likely to
be genuine was selected.
All CNVs that passed the stringent filter criteria were presumed
to be genuine CNVs. In two previous studies, 100% of our
putative CNVs were shown to be technically verifiable when our
filter criteria were employed [20,23].
Table 2. Phenotypic information of patients with a CNV in regions previously associated with SCZ.






1q21 671 1 144,106,312 147,427,061 DEL 295.3 f 33 no passed exams after nine
years of schooling
17 1 144,967,972 147,331,145 DEL 295.3 m 20 no .
579 1 144,967,972 146,293,282 DEL 295.3 f 16 no passed exams after nine
years of schooling
2p16.3 68 2 50,658,484 50,847,759 DEL 295.7 m 14 no passed exams after nine
years of schooling
382 2 50,797,032 50,895,846 DEL 295.4 f 32 . passed A levels (13 years
of schooling)
702 2 50,836,690 50,936,258 DEL 295.3 f 20 no high-school diploma (10
years of schooling)
720 2 50,850,456 51,225,851 DEL 295.3 f 27 yes passed exams after nine
years of schooling
502 2 50,870,615 50,981,293 DEL 295.7 m 45 no passed A levels (13 years
of schooling)
288 2 51,068,497 51,255,180 DEL 295.3 m 22 no passed exams after nine
years of schooling
779 2 50,716,777 50,756,435 DEL 295.3 m 18 no passed A levels (13 years
of schooling)
812 2 50,735,657 50,800,548 DEL 295.3 f 34 no passed A levels (13 years
of schooling)
813 2 50,735,657 50,800,548 DEL 295.3 m 26 no passed A levels (13 years
of schooling)
273 2 50,750,960 50,829,989 DUP 295.3 m 30 yes passed A levels (13 years
of schooling)
361 2 50,912,249 50,948,557 DEL 295.3 m 44 no left school after nine years,
sat no examinations
7q36 228 7 158,456,556 158,812,247 DUP 295.1 f 22 . left school after nine years,
sat no examinations
15q11.2 383 15 20,306,549 20,685,685 DEL 295.4 f 32 no passed exams after nine
years of schooling
107 15 20,317,047 20,778,963 DEL 295.x m 18 no .
16p13.11 149 16 15,032,942 15,988,624 DEL 295.x f 30 . .
558 16 15,032,942 16,197,033 DEL 295.6 f 23 no high-school diploma (10
years of schooling)
332 16 15,036,960 16,197,033 DUP 295.3 m 30 no .
668 16 15,387,380 16,197,033 DEL 295.6 m 18 no passed exams after nine
years of schooling
555 16 15,387,380 18,174,650 DUP 295.1 m 17 no high-school diploma (10
years of schooling)
16p11.2 745 16 29,563,365 30,085,308 DUP 295.6 f 19 yes school for children with
special needs, sat no
examinations
22q11.2 252 22 17,257,787 19,792,353 DEL 295.3 f . . passed exams after nine
years of schooling
775 22 17,257,787 19,792,353 DEL 295.3 f 16 yes passed exams after nine
years of schooling
Chr, chromosome; DEL, deletion; DUP, duplication; Diagnosis, DSM-IV diagnosis; f, female; m, male; AAO, age-at-onset; Family history SCZ, any fist degree relative with
schizophrenia; ., missing data; Position according to NCBI built 36.
doi:10.1371/journal.pone.0064035.t002
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Statistical analysis of CNVs
The datasets generated by QuantiSNP and PennCNV were
analyzed using PLINK (version 1.07, http://pngu.mgh.harvard.
edu/,purcell/plink/index.shtml [24]). To test for associations
between SCZ and CNVs in specific chromosomal regions, Fisher’s
exact test was applied to calculate P-values and odds ratios.
CNVs in regions previously associated with SCZ
The presence in our dataset of CNVs previously shown to be
associated with SCZ in at least two independent studies was
examined. To be included in our analysis, the CNVs derived from
our dataset had to overlap $80% with the reported CNVs. CNVs
in 16p13.11 had to overlap $80% with interval II, as described by
Ingason et al. [10]. For CNVs in 2p16.3, we considered all CNVs
that affected the gene neurexin-1 and spanned $10 consecutive
SNPs. We allowed for the inclusion of smaller deletions and
duplications because smaller CNVs in NRXN1 were previously
reported to be associated with schizophrenia [5]. All CNVs
affected NRXN1 directly and only five out of 11 patients had a
CNV smaller than 30 SNPs. Each CNV was visually confirmed in
the GenomeStudio.
Results
Data collection of high-quality CNVs
After application of all filter criteria, data from 1,637 patients
and 1,627 controls remained. Using QuantiSNP, 2,487 CNVs
passed our set of filter criteria (0.76 CNVs per individual); for
PennCNV, 2,430 CNVs passed all filters (0.74 CNVs per
individual). After merging the two datasets and removing those
CNVs that were detected by only one program, 2,366 CNVs (0.73
CNVs per individual) remained in our dataset. All CNVs derived
from our patients are provided in table S1. Individual genotype
and intensity data can be obtained on a collaborative basis.
Genome-wide association analysis
We performed a genome-wide analysis to uncover associations
between specific CNVs and SCZ, but we did not detect any
specific CNVs to be nominally significantly associated with the
disorder. However, it is noteworthy that, in our dataset, a CNV
had to be identified in at least six patients and in no control to
reach a nominally significant P-value.
CNVs in regions previously associated with SCZ
In total, we analyzed 11 CNV regions (CNVRs) that are
established risk factors for SCZ susceptibility and detected a higher
proportion of CNVs overlapping $80% with those regions in
patients than in the controls. We identified 20 microdeletions and
five microduplications in 1,637 patients as compared with 12
microdeletions in 1,627 controls (see Table 1, P-value: 0.051). No
duplication in any of the 11 CNVRs was detected among the
controls. In our dataset, none of the specific CNVs was
individually significantly associated with SCZ. None of our
patients carried a CNV in 3q29, 15q13.3, 17p12, or 17q12.
However, in 1q21.1, 2p16.3, and 22q11.2, we identified a higher
proportion of microdeletions in patients as compared with controls
(3/1,637 in patients versus 1/1,627 in controls in 1q21.1; 10/
1,637 in patients versus 5/1,627 in controls in 2p16.3, and 2/
1,637 in patients versus 0/1,627 in controls in 22q11.2). We
detected a microduplication in 7q36.3 and 16p11.2 in the patients,
whereas neither of these microduplications was detected in the
controls. In 15q11.2 we identified a higher proportion of
microdeletions in controls as compared with patients (2/1,637 in
patients versus 3/1,627 in controls. Phenotypic information for the
CNV carriers is provided in Table 2.
Discussion
In this study, we provide a unique, high-quality CNV data
collection in a clinically well characterized sample of 1,637
patients with SCZ and SCZA. Applying conservative, stringent
filter criteria is expected to reduce type I errors, whereas type II
errors are expected to increase. This strategy benefitted the
genome-wide CNV dataset for two main reasons: (i) larger CNVs
were selected for and these were more likely to have a stronger
impact on the phenotype than smaller CNVs, and (ii) only CNVs
that spanned a fairly large number of consecutive SNPs and that
were detected by two CNV programs were selected, which
increased the likelihood of obtaining genuine CNVs. In our
previous experience, all microduplications and microdeletions
fulfilling our quality criteria can be successfully verified by
quantitative real-time PCR using TaqMan Copy Number Assays
(Applied Biosystem, Foster City, CA, USA) or Fast SYBRH Green
(Life Technologies, Carlsbad, California, USA), or pre-designed
SALSAH MLPAH (Multiplex Ligation-dependent Probe Amplifi-
cation) kits (MRC Holland, Amsterdam, the Netherlands) [20,23].
This high CNV reliability is important as we hope the dataset will
serve as a resource for other investigators who might wish to
combine their own data with our data with the aim of achieving a
higher detection rate for associations between individual CNVs
and this disease.
We checked our dataset for the presence of CNVs in regions
previously associated with SCZ. Even though none of the CNVs in
the 11 analyzed CNVRs reached a significant P-value, we found a
higher frequency of CNVs in 1q21.1, 2p16.3, 7q36.3, 16p13.11,
16p11.2, and 22q11.2 in patients than in the controls. Therefore,
our study provides additional support that CNVs in these regions
are genetic risk factors for SCZ. None of our patients carried a
CNV in 3q29, 15q13.3, 17p12, or 17q12. The frequency of SCZ-
associated CNVs is estimated to be low (e.g. ,1% for CNVs in
3q29 and 17q12; [11,13]). Therefore, one likely explanation for a
lack of CNVs in these regions is that our dataset, despite its
reasonable size, might still not be sufficiently powered to detect
very rare CNVs. However, our study confirms the low frequency
of risk-carrying CNVs in controls.
The main limitation of the present study is, at the same time, its
greatest strength. Applying stringent filter criteria could have led to
the removal of smaller, and potentially true, CNVs from our
dataset. Conversely, this approach ensured that the reported
CNVs were of high quality.
Supporting Information
Table S1 List of CNVs in patients.
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